Sensitivity Comparison of Follow-up MRI Between Acute Cerebral and Cerebellar Cortical Microinfarctions ( CMI )Microinfarctions (CMI)

Sensitivity Comparison of Follow-up MRI Between Acute Cerebral and Cerebellar Cortical Microinfarctions ( CMI )

Cerebral cortical microinfarctions (CMI) are frequently observed on MRI and histology studies, especially in elderly patients and in patients with cognitive dysfunction. The majority of these studies analysed chronic cerebral CMI lesions.

The few studies reporting on temporal dynamics of MRI signal of acute cerebral CMI showed very low sensibility for persisting signal changes on follow-up MRI on standard MRI sequences. A retrospective study, analysing follow-up 3T MRI in 25 patients with acute cerebral CMI (defined as ≤10 mm on DWI), showed a chronic cerebral CMI detection rate of only 16% on T2-weighted and 5% on FLAIR imaging after a mean follow-up period of 33 months (with a very wide range of 0.5-142 months). Another 3T MRI study including seven patients showed disappearance of all acute cerebral very small-sized CMI (defined as <5 mm size on initial DWI) on all follow-up MRI sequences (T1- and T2-weighted and FLAIR imaging, performed after one month).

Recently, it has been shown that chronic relatively small (<20 mm) cerebellar cortical infarctions (based on diffusion-weighted imaging) were frequently observed in acute stroke patients, especially in case of cardioembolic stroke (with chronic small cerebellar cortical infarctions observed in 32% of cases). The high prevalence of these chronic small cerebellar cortical infarctions suggest a possible higher detection rate of chronic small-sized infarction in the cerebellum compared to the supratentorial brain.

Study Overview

• Status: Recruiting
• Conditions: Acute Cerebral and Cerebellar Cortical Microinfarctions (CMI)
• Intervention / Treatment: Other: None, purely observational study

• Study Type: Observational
• Enrollment (Estimated): 59

Contacts and Locations

• Study Contact: Name: Dimitri RENARD; Phone Number: +33466685808; Email: dimitri.renard@chu-nimes.fr

Study Locations

• France
  • Nîmes, France, 30029
    • Recruiting
    • CHU de Nîmes
    • Contact: Dimitri RENARD; Phone Number: +33466685808; Email: dimitri.renard@chu-nimes.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: N/A

• Sampling Method: Probability Sample

Study Population

Patient admitted to Nîmes University Hospital between February 2021 and June 2023 with initial MRI performed within one week after symptom onset, symptomatic brain infarction confirmed by DWI, and the presence of acute cerebral and/or cerebellar CMI

Description

Inclusion Criteria:

Patients admitted to our stroke centre between February 2021 and June 2023 with the following inclusion criteria:

• age >18 years,
• initial MRI performed within one week after symptom onset,
• symptomatic brain infarction confirmed by DWI,
• presence of acute cerebral and/or cerebellar CMI

Exclusion Criteria:

• age < 18 years

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
acute cerebral and/or cerebellar CMI; Patients with acute cerebral and/or cerebellar CMI	Other: None, purely observational study; None, purely observational study

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Chronic CMI	Detection rate of chronic CMI on follow-up MRI used in daily clinical practice after initial acute cerebral and cerebellar CMI (≤10 mm) (Nb)	6 monthes
CMI localisations	Compare initial acute cerebral and cerebellar CMI (≤10 mm) localisation (cerebral or cerebellar)	6 monthes

Collaborators and Investigators

• Sponsor: Centre Hospitalier Universitaire de Nīmes
• Investigators: Study Director: Anissa MEGZARI, Centre Hospitalier Universitaire de Nīmes

Study record dates

Study Major Dates

• Study Start (Actual): February 15, 2024
• Primary Completion (Estimated): December 1, 2024
• Study Completion (Estimated): December 1, 2024

Study Registration Dates

• First Submitted: January 12, 2024
• First Submitted That Met QC Criteria: January 12, 2024
• First Posted (Actual): January 23, 2024

Study Record Updates

• Last Update Posted (Actual): March 29, 2024
• Last Update Submitted That Met QC Criteria: March 28, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Immune System Diseases; Hypersensitivity
• Other Study ID Numbers: LOCAL/2023/DR-01

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No